Welcome to our dedicated page for Argent BioPharma news (Ticker: RGTLF), a resource for investors and traders seeking the latest updates and insights on Argent BioPharma stock.
Argent BioPharma (RGTLF) is a clinical-stage biopharmaceutical innovator advancing treatments for CNS and immune disorders through neuroimmunology and nano-medicine. This page provides centralized access to official company announcements and verified news updates.
Investors and researchers will find timely reports on clinical trial progress, strategic collaborations (including ongoing work with SINTEF), and regulatory milestones. Key updates cover the development of the Neuro-Immune Modulatory System, nano-encapsulation advancements, and pipeline expansions.
All content is rigorously curated to ensure accuracy and relevance. Regular visitors gain insights into how RGTLF's research addresses antibiotic resistance, chronic inflammation, and neurodegenerative conditions through its proprietary technologies.
Bookmark this page for direct access to earnings reports, partnership announcements, and scientific breakthroughs. Check back frequently for the latest developments shaping Argent BioPharma's position in biopharmaceutical innovation.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) has announced its entry into the German pharmaceutical market, securing initial purchase orders for CannEpil® and CogniCann® following regulatory approval. Germany, being Europe's largest healthcare market, represents a significant commercial milestone for the company's European expansion strategy.
The clinical-stage biopharmaceutical company has also completed the transfer of its EU GMP-certified manufacturing facilities in Slovenia and Malta to third-party operators. This operational restructuring is expected to generate annual cost savings of over $1 million while maintaining GMP compliance. The freed capital will be directed towards accelerating R&D initiatives and clinical trials across core therapeutic programs.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) has announced positive Phase IIb clinical trial results for its novel anti-inflammatory treatment, CimetrA®. The trial demonstrated significant benefits in COVID-19 patients, including:
- No drug-related adverse events
- Faster clinical improvement compared to placebo (WHO Ordinal Scale)
- Reduced inflammation with modulation of key markers (IL-6, IL-1β, TNF-α)
- Improved quality of life trends
The company is also developing CannEpil®, an oral mucosal solution with high-CBD and low-THC formulation, designed for severe epilepsy treatment. The drug is currently making progress in the UK market.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) reports progress in its collaboration with SINTEF on enhancing antimicrobial therapies for chronic wounds and oncologic wound care. The company has advanced its proprietary antimicrobial compounds using nano-encapsulation technology to improve drug efficacy and targeted delivery.
Key achievements include establishing standardized in vitro assays, identifying Synthetic Wound Fluid (SWF) as the optimal testing medium, and selecting promising APIs with pH-dependent antimicrobial activity. The research targets diabetic foot ulcers, pressure sores, post-surgical infections, and non-melanoma skin cancer excisions.
The next phase will focus on refining API combinations for nano-encapsulation and conducting Minimum Inhibitory Concentration studies. The initiative aims to address biofilm formation, antibiotic resistance, and chronic infections in a global advanced wound care market projected to exceed $15 billion by 2030.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) has successfully completed a US$4.5 million capital raise through a placement of 5,625,000 Units at US$0.80 each. Each Unit includes two ordinary shares and one warrant exercisable at US$0.55 with a three-year expiry.
The placement will be executed in two tranches: Tranche 1 with 5,000,000 shares and 2,500,000 warrants issued immediately, and Tranche 2 with 6,250,000 shares and 3,125,000 warrants subject to shareholder approval. The shares are priced at US$0.40, representing a 370% premium to the 15-day VWAP.
The funds will support Argent's drug development pipeline, particularly CannEpil® clinical studies. The company is conducting a strategic review following LSE delisting and preparing for US National Listing. Sputnik Enterprises , acting as corporate advisor, will receive a 5% cash fee and 1,125,000 warrants.
Argent BioPharma (ASX: RGT) (OTCQB: RGTLF) has successfully completed a US$4.5 million capital raise through a placement of 5,625,000 Units at US$0.80 each. Each Unit includes two ordinary shares and one warrant exercisable at US$0.55 with a three-year expiry.
The placement will be executed in two tranches: Tranche 1 with 5,000,000 shares and 2,500,000 warrants issued immediately, and Tranche 2 with 6,250,000 shares and 3,125,000 warrants pending shareholder approval. The placement shares are priced at US$0.40, representing a 370% premium to the 15-day VWAP.
The funds will support Argent's drug development pipeline, particularly CannEpil® clinical studies. The company is conducting a strategic review following LSE delisting and preparing for US National Listing. Sputnik Enterprises , acting as corporate advisor, will receive a 5% cash fee and 1,125,000 warrants.
FAQ
What is the current stock price of Argent BioPharma (RGTLF)?
What is the market cap of Argent BioPharma (RGTLF)?
